Blood
Anemia (General)
Anemia (General) is a blood condition, but the term alone does not identify the specific context or underlying reason involved. The evidence described includes Vitamin A in relation to transfusion needs in preterm infants and Vitamin B6 (Pyridoxine) for pyridoxine-responsive sideroblastic anemia.
Anemia (General) is categorized under blood conditions.
This list shows research findings, not treatments. Nothing here replaces medical care. If you have this condition, talk to a doctor.
May not suit people with this condition
Supplements and practices linked to problems for people with this condition.
Cupping TherapypracticeUnclear
Wet cupping removes blood, so additional blood loss may worsen active, clinically significant anemia.
Open the Cupping Therapy pageOzone TherapypracticeUnclear
Significant anemia is a contraindication to blood-based Ozone Therapy procedures because blood removal and oxidative hemolysis could further reduce oxygen-carrying capacity.
Open the Ozone Therapy page
The expert view shows every study, dose protocol and source.
What may help
Interventions recorded as helping with this conditionNothing in this library is currently recorded as helping with Anemia (General). That means nothing is on file — not that nothing exists. Only 107 of 338 catalogued supplements have a written-up profile so far.
What to avoid
Interventions recorded as making it worse2 listedHighest probability
- →PracticesCupping TherapyCertaintyLowSourceReference knowledge
Wet cupping removes blood, so additional blood loss may worsen active, clinically significant anemia.
Open Cupping TherapyRationale
Wet cupping removes blood, so active clinically significant anemia can be worsened by additional blood loss.
- →PracticesOzone TherapyCertaintyLowSourceReference knowledge
Significant anemia is a contraindication to blood-based Ozone Therapy procedures because blood removal and oxidative hemolysis could further reduce oxygen-carrying capacity.
Open Ozone TherapyRationale
Significant anemia is a contraindication to blood-based ozone procedures because blood removal and oxidative hemolysis could further reduce oxygen-carrying capacity.
How to read the evidence
Evidence tier — overall strength of the evidence for the whole compound
- StrongWell established — backed by strong, consistent human research.
- ModerateSome genuine support, but mostly from small or lower-quality studies. Promising, not proven.
- PreliminaryEarly-stage evidence — a promising hypothesis, not an established effect yet.
- LimitedVery limited evidence — treat this as a hypothesis, not proof.
- InsufficientNot enough good evidence to draw conclusions yet.
Certainty — how sure we can be that the effect is real
- Very highVery sure — strong, consistent evidence
- HighFairly sure — consistent evidence from good studies
- MediumModerately sure — new studies could change this
- LowNot sure — little or mixed evidence
- Very lowVery unsure — almost no usable evidence
Source — where the data comes from
- Meta-analysisPooled analysis of many trials — the strongest evidence
- RCTRandomized controlled trial — a strong human study design
- ClinicalA human clinical study
- Reference knowledgeFrom general health-science or pharmacology references, not a study of this exact claim
- Animal researchStudied in animals, not humans
- Community reportsAggregated user reports — anecdotal signal, not evidence
- TheoreticalMechanism-based reasoning, not yet tested
Study grade — quality of each underlying study (A best, D weakest)
- AHigh-quality — strong, consistent human trials
- BGood — solid evidence with some limitations
- CModerate — limited, small, or mixed-quality studies
- DWeak — preliminary, indirect, or animal-only
Confidence — how strongly the sources back a finding
A 0–100 score from study quality and agreement
Most supplement evidence is graded C–D. Read it as preliminary signal, not proof.
Full write-up
What is it
Anemia (General) is a blood condition, but the term alone does not identify the specific context or underlying reason involved. The evidence described includes Vitamin A in relation to transfusion needs in preterm infants and Vitamin B6 (Pyridoxine) for pyridoxine-responsive sideroblastic anemia. These examples should not be treated as interchangeable options. Anyone with anemia should discuss its evaluation and management with a clinician.
Evidence-backed options
The evidence associated with anemia is narrow and applies to specific contexts rather than to anemia as a whole. Vitamin A is supported by clinical evidence with low probability of benefit in a study of preterm infants, where earlier vitamin AD supplementation was associated with reduced transfusion needs. Vitamin B6 (Pyridoxine) is described in pharmacology references as an established treatment for pyridoxine-responsive sideroblastic anemia, a specific anemia subtype in which pyridoxal phosphate is required for heme synthesis.
These findings should not be interpreted as showing that either option addresses every form of anemia. The Vitamin A finding concerns preterm infants, while the Vitamin B6 reference concerns a responsive subtype. No treatment duration or time to effect is specified here, so the evidence does not establish how long either option was taken or how quickly changes appeared. Clinical evaluation is important because the relevance of an option depends on the type and cause of anemia.
What to avoid
Ozone Therapy is flagged for significant anemia when it involves blood-based procedures. These procedures include blood removal, which may further reduce the amount of blood available to carry oxygen. The oxidative process involved may also cause hemolysis, potentially reducing oxygen-carrying capacity further. Together, these concerns are relevant because anemia already involves reduced oxygen delivery capacity.
This caution applies specifically to blood-based ozone procedures rather than necessarily to every form of ozone-related treatment. Anyone with a medical condition such as anemia can discuss the relevance of this concern and any treatment options with a clinician.